Worldwide the COVID-19 (coronavirus) outbreak has created major challenges for clinicians. Lack of proven pharmacological therapies for the treatment of COVID-19 has resulted in increased mortality rates. Corticosteroids were extensively used during outbreaks of Severe Acute Respiratory Syndrome (SARS)-CoV as well as the Middle East Respiratory Syndrome (MERS)-CoV. This technique has led to the application of corticosteroids for COVID-19 patient, in combination with other therapeutic agents. However, the WHO (World Health Organization) advises against the use of corticosteroids due to the lack of reliable clinical evidence. Thus, companies in the hydrocortisone market are unable to capitalize on the needs of COVID-19 patients when actually there is an unprecedented demand for drugs that fight off the infection.
Companies in the hydrocortisone market are increasing efforts to identify the harm and benefits caused by corticosteroids for the treatment of coronavirus.
Several children are prone to the risks of adrenal insufficiency, since they are unable to mount an endogenous cortisol response to stress. Such children usually receive treatment at home by seeking telephone advices from doctors. Thus, companies in the hydrocortisone market should tap into opportunities in child care to broaden their revenue streams. As such, adrenocortical insufficiency is one of the key medical indications that demand hydrocortisone drugs and the market is predicted to reach a value of ~US$ 2 Bn by the end of 2028.
Many children are administered oral corticosteroids such as hydrocortisone, dexamethasone, and prednisolone on a daily basis since adrenocortical insufficiency is potentially life threatening. Problems arising from such medical conditions have fueled the demand for steroid medicines that are generally administered intramuscularly or intravenously, depending on the severity of the clinical situation. Companies in the hydrocortisone market are increasing the availability of hydrocortisone sodium succinate and hydrocortisone sodium phosphate for treatment of children that require extra steroids.
Companies in the hydrocortisone market are introducing medicines that do not require a prescription. For instance, in May 2019, Aflofarm— a supplier of Over the Counter drugs (OTC) and medical devices, announced the launch of Maxicortan, a medicine with double dose of hydrocortisone that can be applied locally on skin inflammations and caters to individuals with atopic dermatitis. As such, dermatitis is one the key medical indications that is creating incremental opportunities for companies in the hydrocortisone market. Therapeutic indications such as allergic contact dermatitis, urticarial, and skin reactions after insect bites are also creating revenue streams for pharmaceutical companies.
On the other hand, dual release hydrocortisone is becoming popular as a metabolism improver agent for patients with adrenal insufficiency. Healthcare professionals are recommending once daily dual release hydrocortisone to provide adequate cortisol exposure time. Since conventional GC (Glucocorticoid) therapy is associated with increased morbidity and mortality, gradual increase in the dosage of dual release hydrocortisone has helped to improve hypoadrenalism patient quality of life.
Septic shock is a life-threatening condition that has led to high mortality rates. Hence, clinicians recommend corticosteroids such as hydrocortisone to reduce the severity of trauma caused in patients. As such, hydrocortisone medicines are subject to intensive investigation in several clinical trials. Currently, low-dose hydrocortisone is being highly publicized for shock reversal, resulting in lesser adverse events among patients. This has led to better clinical outcomes as compared to placebo.
Although hydrocortisone aids in faster resolution of shock than placebo, the optimal dosage for hemodynamic support during septic shock is still unclear. This explains why the hydrocortisone market is progressing at a modest CAGR of ~4% during the forecast period, due to lack of reliable clinical evidence. However, growing awareness about the lowest initial dose of hydrocortisone in adults is helping to revive growth for the hydrocortisone market. This awareness is increasing as a result of the rise in the number of randomized clinical trials.
Analysts’ Viewpoint
The evidences of harm and benefits of corticosteroids have gained prime importance for companies in the hydrocortisone market amidst the coronavirus outbreak. Hydrocortisone medicines are being increasingly used as adjunctive treatment to septic shock.
The glucocorticoid treatment is being combined with hydrocortisone or cortisone acetate for the treatment of adrenal insufficiency (AI) patients. However, this combination treatment has led to overexposure toward GCs, resulting in metabolic dysfunction. Hence, companies should increase awareness of once daily dual release hydrocortisone dose that gradually increases dosage content among AI patients. Companies should gain efficacy in no prescription medicines to increase product uptake among individuals with therapeutic indications such as dermatitis.
Hydrocortisone Market - Segmentation
|
Indication |
Adrenocortical Insufficiency Adrenergic Syndrome High Blood Calcium Thyroiditis Rheumatoid Arthritis Dermatitis Asthma and Chronic Obstructive Pulmonary Disease (COPD) Others |
|
Route of Administration |
Parenteral Oral Topical |
|
Distribution Channel |
Hospital Pharmacies Retail Pharmacies Online Pharmacies |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
The global hydrocortisone market was worth US$ 1 Bn and is projected to reach a value of US$ 2 Bn by the end of 2028
Hydrocortisone market is anticipated to grow at a CAGR of 4% during the forecast period
North America accounted for a major share of the global hydrocortisone market
Hydrocortisone market is driven by rise in cases of adrenocortical insufficiency and increase in investment in research & development are projected to drive the global market during the forecast period
Key players in the global hydrocortisone market include Pfizer, Inc., Novartis AG, Mylan N.V., Hikma Pharmaceuticals Plc, GlaxoSmithKline plc, Cipla Inc., Sun Pharmaceutical Industries Ltd., Abbott Laboratories, and Bayer AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Hydrocortisone Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hydrocortisone Market Analysis and Forecast, 2018–2028
5. Key Insights
5.1. Regulatory Scenario, by Region/globally
6. Global Hydrocortisone Market Analysis and Forecast, by Indication
6.1. Introduction
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Indication, 2018–2028
6.3.1. Adrenocortical Insufficiency
6.3.2. Adrenergic Syndrome
6.3.3. High Blood Calcium
6.3.4. Thyroiditis
6.3.5. Rheumatoid Arthritis
6.3.6. Dermatitis
6.3.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
6.3.8. Others
6.4. Market Attractiveness, by Indication
7. Global Hydrocortisone Market Analysis and Forecast, by Route of Administration
7.1. Introduction
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2018–2028
7.3.1. Parenteral
7.3.2. Oral
7.3.3. Topical
7.3.4. Rectal
7.4. Market Attractiveness, by Route of Administration
8. Global Hydrocortisone Market Analysis and Forecast, by Distribution Channel
8.1. Introduction
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2018–2028
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Hydrocortisone Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Hydrocortisone Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Indication, 2018–2028
10.2.1. Adrenocortical Insufficiency
10.2.2. Adrenergic Syndrome
10.2.3. High Blood Calcium
10.2.4. Thyroiditis
10.2.5. Rheumatoid Arthritis
10.2.6. Dermatitis
10.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
10.2.8. Others
10.3. Market Value Forecast, by Route of Administration, 2018–2028
10.3.1. Parenteral
10.3.2. Oral
10.3.3. Topical
10.3.4. Rectal
10.4. Market Value Forecast, by Distribution Channel, 2018–2028
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2018–2028
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hydrocortisone Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Indication, 2018–2028
11.2.1. Adrenocortical Insufficiency
11.2.2. Adrenergic Syndrome
11.2.3. High Blood Calcium
11.2.4. Thyroiditis
11.2.5. Rheumatoid Arthritis
11.2.6. Dermatitis
11.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
11.2.8. Others
11.3. Market Value Forecast, by Route of Administration, 2018–2028
11.3.1. Parenteral
11.3.2. Oral
11.3.3. Topical
11.3.4. Rectal
11.4. Market Value Forecast, by Distribution Channel, 2018–2028
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2018–2028
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Hydrocortisone Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Indication, 2018–2028
12.2.1. Adrenocortical Insufficiency
12.2.2. Adrenergic Syndrome
12.2.3. High Blood Calcium
12.2.4. Thyroiditis
12.2.5. Rheumatoid Arthritis
12.2.6. Dermatitis
12.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
12.2.8. Others
12.3. Market Value Forecast, by Route of Administration, 2018–2028
12.3.1. Parenteral
12.3.2. Oral
12.3.3. Topical
12.3.4. Rectal
12.4. Market Value Forecast, by Distribution Channel, 2018–2028
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2018–2028
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Hydrocortisone Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Indication, 2018–2028
13.2.1. Adrenocortical Insufficiency
13.2.2. Adrenergic Syndrome
13.2.3. High Blood Calcium
13.2.4. Thyroiditis
13.2.5. Rheumatoid Arthritis
13.2.6. Dermatitis
13.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
13.2.8. Others
13.3. Market Value Forecast, by Route of Administration, 2018–2028
13.3.1. Parenteral
13.3.2. Oral
13.3.3. Topical
13.3.4. Rectal
13.4. Market Value Forecast, by Distribution Channel, 2018–2028
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2018–2028
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Hydrocortisone Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast, by Indication, 2018–2028
14.2.1. Adrenocortical Insufficiency
14.2.2. Adrenergic Syndrome
14.2.3. High Blood Calcium
14.2.4. Thyroiditis
14.2.5. Rheumatoid Arthritis
14.2.6. Dermatitis
14.2.7. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
14.2.8. Others
14.3. Market Value Forecast, by Route of Administration, 2018–2028
14.3.1. Parenteral
14.3.2. Oral
14.3.3. Topical
14.3.4. Rectal
14.4. Market Value Forecast, by Distribution Channel, 2018–2028
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2018–2028
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Indication
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Company Profiles
15.1. Pfizer, Inc.
15.1.1.1. Company Overview
15.1.1.2. Company Financials
15.1.1.3. Growth Strategies
15.1.1.4. SWOT Analysis
15.2. Novartis AG
15.2.1.1. Company Overview
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.3. Mylan N.V.
15.3.1.1. Company Overview
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.4. Hikma Pharmaceuticals Plc
15.4.1.1. Company Overview
15.4.1.2. Company Financials
15.4.1.3. Growth Strategies
15.4.1.4. SWOT Analysis
15.5. GlaxoSmithKline plc
15.5.1.1. Company Overview
15.5.1.2. Company Financials
15.5.1.3. Growth Strategies
15.5.1.4. SWOT Analysis
15.6. Cipla Inc.
15.6.1.1. Company Overview
15.6.1.2. Company Financials
15.6.1.3. Growth Strategies
15.6.1.4. SWOT Analysis
15.7. Sun Pharmaceutical Industries Ltd.
15.7.1.1. Company Overview
15.7.1.2. Company Financials
15.7.1.3. Growth Strategies
15.7.1.4. SWOT Analysis
15.8. Abbott Laboratories
15.8.1.1. Company Overview
15.8.1.2. Company Financials
15.8.1.3. Growth Strategies
15.8.1.4. SWOT Analysis
15.9. Bayer AG
15.9.1.1. Company Overview
15.9.1.2. Company Financials
15.9.1.3. Growth Strategies
15.9.1.4. SWOT Analysis
List of Tables
Table 01: Comparison of Regulatory Requirements for Generic Drugs Dossier Submission in the U.S. and Canada
Table 02: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028
Table 03: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028
Table 04: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 05: Global Hydrocortisone Market Value (US$ Mn) Forecast, by Region, 2018–2028
Table 06: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028
Table 07: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028
Table 08: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 09: North America Hydrocortisone Market Value (US$ Mn) Forecast, by Country, 2018–2028
Table 10: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028
Table 11: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028
Table 12: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 13: Europe Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 14: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028
Table 15: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028
Table 16: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 17: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 18: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028
Table 19: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028
Table 20: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 21: Latin America Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
Table 22: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Indication, 2018–2028
Table 23: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2028
Table 24: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2028
Table 25: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2028
List of Figures
Figure 01: Global Hydrocortisone Market Snapshot
Figure 02: Global Hydrocortisone Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2028
Figure 03: Global Hydrocortisone Market Value (US$ Mn) Forecast, 2018–2028
Figure 04: Regulatory Approval Process - The U.S.
Figure 05: Regulatory Approval Process - Europe
Figure 06: Regulatory Approval Process - Japan
Figure 07: Drug Development
Figure 08: Global Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028
Figure 09: Global Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028
Figure 10: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Adrenocortical Insufficiency, 2018–2028
Figure 11: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Adrenogenital Disorder, 2018–2028
Figure 12: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by High Blood Calcium, 2018–2028
Figure 13: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Thyroiditis, 2018–2028
Figure 14: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Rheumatoid Arthritis, 2018–2028
Figure 15: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Dermatitis, 2018–2028
Figure 16: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Asthma and Chronic Obstructive Pulmonary Disease (COPD), 2018–2028
Figure 17: Global Hydrocortisone Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2018–2028
Figure 18: Global Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028
Figure 19: Global Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028
Figure 20: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Parenteral, 2018–2028
Figure 21: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Oral, 2018–2028
Figure 22: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Topical, 2018–2028
Figure 23: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Rectal, 2018–2028
Figure 24: Global Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028
Figure 25: Global Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028
Figure 26: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2018–2028
Figure 27: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2018–2028
Figure 28: Global Hydrocortisone Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2018–2028
Figure 29: Global Hydrocortisone Market Value Share Analysis, by Region, 2019 and 2028
Figure 30: Global Hydrocortisone Market Attractiveness Analysis, by Region, 2020–2028
Figure 31: North America Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028
Figure 32: North America Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028
Figure 33: North America Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028
Figure 34: North America Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028
Figure 35: North America Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028
Figure 36: North America Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028
Figure 37: North America Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028
Figure 38: North America Hydrocortisone Market Value Share Analysis, by Country, 2019 and 2028
Figure 39: North America Hydrocortisone Market Attractiveness Analysis, by Country, 2020–2028
Figure 40: Europe Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028
Figure 41: Europe Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028
Figure 42: Europe Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028
Figure 43: Europe Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028
Figure 44: Europe Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028
Figure 45: Europe Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028
Figure 46: Europe Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028
Figure 47: Europe Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028
Figure 48: Europe Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 49: Asia Pacific Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028
Figure 50: Asia Pacific Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028
Figure 51: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028
Figure 52: Asia Pacific Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028
Figure 53: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028
Figure 54: Asia Pacific Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028
Figure 55: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028
Figure 56: Asia Pacific Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028
Figure 57: Asia Pacific Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 58: Latin America Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028
Figure 59: Latin America Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028
Figure 60: Latin America Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028
Figure 61: Latin America Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028
Figure 62: Latin America Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028
Figure 63: Latin America Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028
Figure 64: Latin America Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028
Figure 65: Latin America Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028
Figure 66: Latin America Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Figure 67: Middle East & Africa Hydrocortisone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2028
Figure 68: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Indication, 2019 and 2028
Figure 69: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Indication, 2020–2028
Figure 70: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Route of Administration, 2019 and 2028
Figure 71: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Route of Administration, 2020–2028
Figure 72: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Distribution Channel, 2019 and 2028
Figure 73: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Distribution Channel, 2020–2028
Figure 74: Middle East & Africa Hydrocortisone Market Value Share Analysis, by Country/Sub-region, 2019 and 2028
Figure 75: Middle East & Africa Hydrocortisone Market Attractiveness Analysis, by Country/Sub-region, 2020–2028
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hydrocortisone Market
